Bile acid-mediated activation of hepatic stellate cells and myeloid cell leukemia- 1 triggers hepatocarcinogenesis

doi:10.21203/rs.3.rs-4716083/v1

Download PDF

Research Article

Bile acid-mediated activation of hepatic stellate cells and myeloid cell leukemia- 1 triggers hepatocarcinogenesis

https://doi.org/10.21203/rs.3.rs-4716083/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Objective

Activated hepatic stellate cells (HSCs) promote hepatocellular carcinoma (HCC) cell growth and migration. Senescent and cancer-associated fibroblasts express various factors contributing to tumor progression, collectively called the senescence-associated secretory phenotype (SASP). Herein, we investigated the mechanism underlying the bile acid-mediated induction of HSC activation via SASP expression in HCC cells.

Methods

Serum samples from 296 patients with HCC were used to analyze IL-6 levels and survival. IL-6 mRNA levels were quantified using real-time PCR. A mouse xenograft model was used to confirm the role of the SASP. MTT and invasion assays were performed to evaluate the invasive ability of HCC cells (Huh-BAT, SNU-761, and Huh-SR) co-cultured with HSCs (LX-2 cells). Western blotting was performed to investigate the levels of survival signals.

Results

Bile acid increased the expression of mesenchymal markers and myeloid cell leukemia-1 (Mcl-1) and cyclooxygenase-2 (COX-2) proteins in HCC cells and HSCs. Inhibiting Mcl-1 induction or COX-2 activity decreased bile acid-mediated HCC invasion. Takeda G protein-coupled receptor 5 (TGR5) activation-dependent Mcl-1 and COX-2 expression enhanced gene transcription. Bile acid significantly increased IL-6 levels and HCC cell invasion in HSC/HCC cell co-cultures compared to HCC cell monocultures. The IL-6 + MoRAL score also showed significant discrimination in overall survival (Harrell’s c-index 0.765, p < 0.0001) of HCC patients. A mouse xenograft model revealed that Mcl-1 short hairpin RNA transfection, not celecoxib treatment, significantly suppressed Huh-SR cell growth.

Conclusion

Bile acid-mediated activation of HSCs enhances the proliferation and invasion of HCC cells via the expression of SASP proteins, including IL-6. TGR-5-dependent Mcl-1 overexpression may be a key factor in hepatocarcinogenesis.

hepatocellular carcinoma

senescence-associated secretory phenotype

invasion

Mcl-1

Bile acid-mediated induction of hepatic stellate cell activation aggravated HCC cell progression.
Bile acid significantly increased IL-6 levels as a result of HSC and HCC crosstalk.
SASP induced the increased expressions of Mcl-1 and COX- in HCC cells and HSCs.

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of cancer-related deaths worldwide.[1] Understanding the molecular mechanisms underlying HCC progression is crucial for developing effective therapeutic strategies.[2] The combination of atezolizumab and bevacizumab[3] significantly increased the overall survival of patients with advanced HCC compared to sorafenib from 13.4 months to 19.2 months.[4] However, there are still unsolved clinical problems, including approximately 26% of non-responders to atezolizumab plus bevacizumab and intolerance to immune-oncologic drugs, such as underlying autoimmune diseases (e.g., ulcerative colitis).[5] Also, 26–30% of non-responders to atezolizumab plus bevacizumab often have poorly differentiated tumor biology and progress very rapidly.[6] Therefore, there is an urgent need to identify novel biomarkers and therapeutic targets for poorly differentiated HCCs.

Recent studies have highlighted the significant role of the senescence-associated secretory phenotype (SASP) in hepatocarcinogenesis, especially in aspect of progression to poor biology.[7] SASP is characterized by the secretion of various pro-inflammatory cytokines, chemokines, and growth factors by senescent cells, contributing to chronic inflammation and tumor promotion. However, the specific involvement of the SASP in HCC pathogenesis and its relationship with hepatic stellate cell (HSC) activation remain poorly elucidated. Although previous studies have explored the pathogenic role of the SASP in various cancer types, including liver cancer, its specific impact on hepatocarcinogenesis remains largely unexplored. The current literature lacks detailed investigations of the interplay between bile acid-mediated HSC activation and the expression of SASP components in HCC cells.

In previous studies, bile acids induced cyclooxygenase-2 (COX-2) and myeloid cell leukemia-1 (Mcl-1) protein expression in HSCs and cholangiocytes, mediating their survival against bile acid-induced apoptosis[8] unlike hepatocytes undergoing apoptosis.[9] COX-2 is an enzyme that is involved in prostanoid metabolism and may promote cellular growth, inhibit apoptosis, and support angiogenesis.[10] Moreover, a growing body of evidence shows that COX-2 expression is correlated to cancer invasion and metastasis by reducing the activity of E-cadherin, inhibiting the separation of cancer cells from tissues via matrix metalloproteinase upregulation.[11] Mcl-1 is a potent anti-apoptotic Bcl-2 family protein induced by various stimuli. Specifically, it blocks the release of cytochrome c, which is required for the intrinsic apoptosis pathway.[12] During liver damage and secondary inflammatory reactions, DNA damage of a significant magnitude might induce cellular senescence.

In the present study, we investigated the mechanism underlying the bile acid-mediated induction of HSC activation via SASP expression in HCC cells. The mechanisms underlying these signaling cascades may provide new targets for preventing HCC progression by inhibiting HSC activation. This study aimed to fill this knowledge gap by elucidating the mechanisms underlying the bile acid-mediated induction of HSC activation and its relationship with the expression of SASP components in hepatocellular carcinoma cells.

Cell lines and co-culture

The following human HCC cell lines and an HSC line were obtained from the Korean cell-line bank (Seoul, Korea) for this study: Huh-7, HepG2, which are well-differentiated HCC cell lines[13]; SNU-761, a poorly differentiated HCC cell line[14]; SNU-3058, a hypovascular HCC cell line [15]; and LX-2, an activated human HSC line[16]. We also established Huh-SR cells in vitro by culturing Huh-7 cells in a culture medium containing sorafenib for three months. The cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Huh-7, HepG2, and LX-2) or RPMI 1640 (SNU-761) supplemented with 10% fetal bovine serum (FBS), 100,000 U/l penicillin, and 100 mg/l streptomycin, with or without 100 nM insulin. Co-culture experiments were performed in serum-free DMEM or RPMI 1640 using 1-µm pore size Transwell inserts (Corning, Lowell, MA, USA), which permitted media diffusion but prevented cell migration. HCC and LX-2 cell lines were incubated alone or together using Transwell inserts under standard culture conditions (20% O₂ and 5% CO₂, 37°C).

Cell proliferation analysis (MTT assay)

Using the CellTiter 96 Aqueous One Solution cell proliferation assay (Promega, Madison, WI, USA), cell proliferation was measured based on the cellular conversion of the colorimetric reagent 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) into soluble formazan by the dehydrogenase enzyme found in metabolically proliferating cells. Following each treatment, 20 µl of dye solution was added into each well of a 96-well plate and incubated for 2 hours. Subsequently, the absorbance was recorded at 490 nm using an enzyme-linked immunosorbent assay (ELISA) plate reader (Molecular Devices, Sunnyvale, CA, USA).

Small interfering RNA (siRNA) transfection

Cells were seeded in a 6-well culture plate (2 × 10⁵ cells/well) in 2 ml antibiotic-free medium supplemented with 10% FBS. At 60–80% confluence, the cells were transfected with siRNAs using a siRNA Transfection Reagent (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) according to the manufacturer’s instructions. The cells were incubated with the siRNAs for 6 hours at 37°C before adding a growth medium containing 20% FBS and antibiotics. After 18 h, the spent medium was replaced with fresh medium containing 10% FBS and antibiotics. At 24 hours after transfection, the cells were used for further experiments.

In vivo subcutaneous xenograft model

Briefly, control short hairpin RNA (shRNA)-transfected Huh-SR cells (5 × 10⁷ cells/mouse) were subcutaneously transplanted into the flanks of nude mice (male, 5 weeks old) in the control group (n = 10). Mcl-1 shRNA-transfected Huh-SR cells (5 × 10⁷ cells/mouse) were subcutaneously transplanted into mice in the study group (n = 10). Control shRNA-transfected Huh-SR cells (5 × 10⁷ cells/mouse) were subcutaneously injected into another group (n = 10), which received celecoxib treatment daily at a dose of 50 mg/kg after tumor budding. Tumor volume was measured using a Vernier caliper and calculated as follows: [length × (width)²]/2. The maximal diameter and volume of each tumor were measured three times per week for three weeks.

Human blood sample collection and cytokine measurement

All human blood samples were provided by the NCC BioBank of the National Cancer Center, Korea. The serum was stored without preservative at − 70℃ and then thawed just prior to testing. IL-6 levels were determined using commercially available human IL-6 ELISA kit supplied by Abcam (ab178013) from serum samples of 296 patients with HCC. All samples were assayed in duplicate.

Immunoblot analysis

Cells were lysed for 20 minutes on ice with lysis buffer and centrifuged at 14,000 ×g for 10 minutes at 4°C. Samples were resolved via sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membranes, blotted with the appropriate primary antibodies (1:1000 dilution), and treated with the corresponding peroxidase-conjugated secondary antibodies (Biosource International, Camarillo, CA, USA). The bound antibodies were visualized using a chemiluminescent substrate (ECL; Amersham, Arlington Heights, IL) and exposed to Kodak X-OMAT film (Kodak, New Haven, CT). Rabbit anti-REG3A antibodies were obtained from Abcam (Cambridge, UK; ab95316). Primary antibodies, including rabbit anti-phospho-p42/44 mitogen-activated protein kinase (MAPK), anti-phospho-Akt, rabbit anti-c-Myc, rabbit anti-caspase 8, anti-caspase 9, and anti-caspase 7 (cleaved) were purchased from Cell Signaling Technology (Danvers, MA, USA). Goat anti-actin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Densitometric analyses were performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

Real-time polymerase chain reaction (qPCR) analysis

Total RNA was extracted from HSC or HCC cells using the Trizol Reagent (Invitrogen, Carlsbad, CA, USA). cDNA templates were prepared using random oligo (dT) primers and Moloney Murine Leukemia Virus reverse transcriptase. After reverse transcription, the cDNA template was amplified via PCR using Taq polymerase (Invitrogen). COX-2 and Mcl-1 mRNA was quantitated using real-time PCR and the following primers: COX-2 forward, 5′-TGAAACCCACTCCAAAACA-3′, reverse, 5′-CCCATGGGCATTCAATAAAC-3′; Mcl-1 forward, 5′-ATGCTTCGGAAACTGGACAT-3′, reverse, 5′-TCCTGATGCCACCTTCTAGG-3′. For gene expression quantification, we used a real-time PCR (LightCycler; Roche Molecular Biochemicals, Mannheim, Germany) with SYBR green as a fluorophore (Molecular Probes, Eugene, OR, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expression was used as a control. The relative intensity of the COX-2 and Mcl-1 bands were compared to that of GAPDH using the 2^–ΔΔCt method. All PCR experiments were performed in triplicate.

Statistical analyses

Statistical analyses were performed using PASW version 21.0 (SPSS Inc., Chicago, IL, USA). All experimental results were obtained from three independent experiments using cells from three separate isolations and presented as the mean ± standard deviation (SD). The Mann–Whitney U test was used for non-parametric measures. For comparisons between groups, data were analyzed using the Mann–Whitney U test or one-way ANOVA.

The Kaplan–Meier method was used to estimate overall survival. A multivariate Cox proportional hazards regression analysis was performed to derive a model. If there was positive collinearity between the covariates, the most objective and easily applicable variable was selected as the representative variable for creating the model. The output of the model was expressed as a coefficient that was used to compute the hazard ratio (HR). In addition, the coefficients were used to calculate the risk score, which was used to predict the tumor recurrence rate. The discrimination function was evaluated using Harrell’s concordance index (c). For all tests, p < 0.05 was considered statistically significant.

Ethics statement

Ethics approval

was obtained from the Ethics Committee of the National Cancer Center, Korea. This study was conducted in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health. The in vivo study protocol was approved by the Institutional Animal Care and Use Committee (NCC-22-771) of the National Cancer Center of Korea. The study was reported in accordance with ARRIVE guidelines. All in vivo surgical procedures were performed under anesthesia with 2,2,2-tribromoethanol, and efforts were made to minimize suffering.

All experiments involving human tissues were approved by the Institutional Review Board of the National Cancer Center (NCC2022-0200). The period for serum samples of the study subjects was from May, 2002, to December, 2013, and the period for accessing medical records was from May, 2002, to December, 2021. Participant consent was waived by the Institutional Review Board of National Cancer Center, Korea.

Bile acid significantly increased the invasion of HSCs

Using an invasion assay, we evaluated whether bile acid treatment increased the invasion of HSCs and examined how SASP contributes to this phenomenon. Treatment with 50 µM deoxycholic acid (DC) increased the invasion of HSCs (Fig. 1A). Treatment of LX-2 cells with DC also significantly increased the levels of IL-6 or IL-8 as determined using real-time PCR (Fig. 1B). These findings indicate that bile acids significantly increased the invasion of HSCs via IL-6 or IL-8, which are some of the most important SASP factors. The treatment of LX-2 cells with DC also increased Mcl-1 and COX-2 protein expression (Fig. 1C).

The selective inhibition of Mcl-1 or COX-2 attenuates HSC invasion and IL-8 production

LX-2 cells were transfected with a Mcl-1-specific siRNA to selectively inhibit Mcl-1 induction. While the treatment of LX-2 cells with DC in the control group significantly increased HSC invasion, Mcl-1 siRNA-transfected LX-2 cells treated with DC showed an attenuated degree of HSC invasion (Fig. 2A). Similarly, COX-2 inhibition by celecoxib attenuated bile acid-mediated HSC invasion, while increased invasion was observed in cells not treated with 20 µM celecoxib (Fig. 2B). We found that inhibitors of either Mcl-1 (via siRNA transfection) or COX-2 (using celecoxib) attenuated bile acid-mediated HSC invasion.

We also tested whether the selective inhibition of Mcl-1 or COX-2 decreased the bile acid-mediated increase in IL-8 levels. We found that the siRNA-mediated inhibition of Mcl-1 significantly diminished IL-8 levels regardless of DC treatment (Fig. 2C). The celecoxib-mediated selective inhibition of COX-2 resulted in a robust decrease in the levels of IL-8 without DC treatment; however, no significant change in the expression of IL-8 was detected with DC treatment (Fig. 2C). These findings further suggest that SASP (i.e., IL-8) induction is regulated by Mcl-1 and COX-2, with Mcl-1 having a greater impact than COX-2.

Crosstalk of HCCs and HSCs increased SASP, COX2, and Mcl-1 levels

We then examined whether the co-culture of HCC cells with HSCs increased the levels of IL-6 or IL-8. Compared to HCC cells (Huh-SR or SNU-761) cultured alone, co-culture with LX-2 cells significantly increased the mRNA levels of IL-6 or IL-8 (Fig. 3A). In addition, co-culturing HCC cells with LX-2 cells significantly increased Mcl-1 and COX-2 protein expression levels compared to their respective monocultures (Fig. 3B).

To selectively inhibit Mcl-1 induction, HCC cells were transfected with a Mcl-1-specific siRNA. Mcl-1 siRNA-transfected HCC cells treated with DC showed reduced expression of IL-6 or IL-8 mRNA (Fig. 3C). Similarly, COX-2 inhibition by celecoxib attenuated the bile acid-induced IL-6 or IL-8 mRNA expression in HCC cells (Fig. 3C).

Upregulated mRNA expression of IL-6 in patients with HCC was correlated with poor overall survival

Next, 168 serum samples from patients with HCC from the National Cancer Center Biobank were used to determine serum ELISA levels. Supplementary Table 1 presents the baseline patient characteristics. The median age was 56 years, and the median level of IL-6 was 5.62 pg/mL (interquartile range, 3.58–14.833). Cox proportional hazard analyses were performed to identify the significant factors for overall survival. Among these variables, we used the square root values of the serum alpha-fetoprotein (AFP) and protein induced by vitamin K antagonist-II (PIVKA-II) levels to fit normal distributions. In the univariate analysis, the number of tumors, tumor size, Child-Pugh score, \(\:\sqrt{\text{S}\text{e}\text{r}\text{u}\text{m}\:\text{A}\text{F}\text{P}}\), \(\:\sqrt{\text{S}\text{e}\text{r}\text{u}\text{m}\:\text{P}\text{I}\text{V}\text{K}\text{A}-\text{I}\text{I}}\), IL-6, and the MoRAL score[17] (\(\:11\:\times\:\:\sqrt{\text{P}\text{I}\text{V}\text{K}\text{A}-\text{I}\text{I}\:}+\:2\:\times\:\:\sqrt{\text{A}\text{F}\text{P}}\)) were significantly associated with the overall survival of study subjects (Supplementary Table 2). There were significant confounding effects between the tumor factors and serum tumor markers; thus, we used serum AFP and PIVKA-II levels in the multivariate analysis, which were objective and reproducible. Multivariate Cox regression analysis showed that IL-6 (HR = 1.011, p < 0.0001) and the MoRAL score (HR = 1.0004, p < 0.0001) were independently associated with the overall survival of patients with HCC. At a cut-off of 5.973, serum IL-6 levels significantly discriminated the OS of patients with HCC with a c-index of 0.741 (Fig. 4A). Based on the Cox proportional hazards model, the risk score was calculated as the IL-6 + MoRAL score. The c-index of the MoRAL score on overall survival was 0.765 (95% confidence interval [CI]: 0.719–0.808) with a cut-off of 172.22, which showed higher performance in predicting overall survival compared to IL-6 or the MoRAL score alone (Supplementary Table 3, Fig. 4B).

Bile acid or IL-6 treatment significantly increased the invasion of HCC cells through the COX2 and Mcl-1 pathways

Next, we evaluated whether bile acids or human IL-6 treatment increased the invasion of HCC cells and examined how the SASP contributes to this phenomenon. The invasion of HCC cells (Huh-SR or SNU-3058) significantly increased after treatment with 50 µM DC (Fig. 5A) or 200 ng/ml human IL-6 (Fig. 5B). Co-culturing HCC cells with HSCs also increased the levels of epithelial-mesenchymal transition (EMT) markers, including fibronectin, N-cadherin, E-cadherin, vimentin, α-SMA, and CK19 compared to HCC cell monocultures (Fig. 5C). In addition, Mcl-1 siRNA-transfected HCC cells treated with DC showed an attenuated expression of EMT markers (Fig. 5D). The downregulation of the Mcl-1 pathway significantly suppressed Huh-SR cell invasion (Fig. 5E).

The selective inhibition of Mcl-1 or COX-2 attenuates the proliferation of HCC cells, which had been enhanced by crosstalk with HSCs

Initially, we examined whether co-culture with HSCs and bile acid treatment could modulate the proliferation of HCC cells. Co-culture with LX-2 cells significantly increased the proliferation of HCC cells compared to HCC cell monocultures. Treatment with a low concentration of DC (50 µM) slightly increased HCC cell proliferation, especially in SNU-3058 cells (Fig. 6A). These findings indicate that the proliferation of HCC cells was enhanced by crosstalk between HCC cells and HSCs under SASP activation.

Mcl-1 siRNA transfection and DC treatment attenuated proliferation in HCC cells (Fig. 6B). Similarly, COX-2 inhibition by celecoxib resulted in the attenuation of bile acid-mediated HCC cell proliferation. In addition, co-treatment of HCC cells (Huh-SR, SNU-3058, and SNU-761) with celecoxib and Mcl-1 siRNA significantly suppressed their proliferation.

Interestingly, the co-culture of HCC cells with LX-2 cells under DC treatment significantly increased the protein expression of the survival pathways, including the mTOR, PARP, Akt, ERK, and YAP pathways (Fig. 6C). In addition, Mcl-1 siRNA-transfected HCC cells treated with DC attenuated the expression of these proteins (Fig. 6D).

The selective inhibition of TGR-5 suppressed bile acid-mediated HSC and HCC cell invasion and IL-6/-8 expression

To further elucidate the pathway regulating the bile acid-induced SASP, LX-2, and HCC cells were treated with MDL-12,330A, a Takeda G protein-coupled receptor 5 (TGR5) inhibitor (10 µM). TGR5, also known as G protein-coupled bile acid receptor 1 (GPBAR1) or membrane-type receptor for bile acids (M-BAR), functions as a cell surface receptor for bile acids and induces the production of intracellular cAMP and the activation of the MAPK pathway. To demonstrate the TGR-5-dependent induction of the SASP (i.e., IL-6 or IL-8), LX-2 or HCC cells were treated with a TGR-5 inhibitor in the absence or presence of DC. As shown in Fig. 7A, while cells treated with the TGR-5 inhibitor in the absence of DC showed increased expression levels of IL-6 or IL-8, cells treated with the TGR-5 inhibitor and DC showed the opposite. These findings collectively indicate that SASP induction (i.e., IL-6 or IL-8), as well as Mcl-1 and COX-2, is due to transcriptional enhancement dependent on TGR-5 activation. As shown in Fig. 7B, cells treated with a TGR-5 inhibitor also showed reduced bile acid-mediated HSC or HCC cell invasion under DC treatment.

Modulation of Mcl-1 expression in HCC cells showed anti-tumor effects in an in vivo xenograft mouse model

The potential anti-proliferative effects of Mcl-1 downregulation were investigated using shRNA transfection in Huh-SR cells and an in vivo xenograft mouse model. The growth of liver tumors was significantly inhibited in the Mcl-1 shRNA-transfected group (n = 10) compared to that in the control group (n = 10) during the 19 days after tumor budding (Fig. 8A; p < 0.05). Oral treatment with celecoxib (50 mg/kg per day, n = 10) for 19 days after tumor budding did not significantly suppress tumor growth compared with the control group (data not shown). We also performed immunohistochemical staining for Mcl-1 in the HCC tissues at the end of the in vivo study (Fig. 8B). Mcl-1 protein expression was significantly suppressed in Mcl-1 shRNA-transfected HCC cells compared to control shRNA-transfected HCC cells. Mcl-1 shRNA transfection also attenuated the protein expressions of β-catenin and YAP (Fig. 8C), which are common and novel markers of hepatocarcinogenesis, respectively.

In this study, we identified a novel target for hepatocellular carcinoma (HCC) treatment, Mcl-1, which was modulated through a TGR-5-dependent mechanism in response to elevated IL-6 levels induced by SASP in the tumor microenvironment. This effect originates from the communication between HCC cells and HSCs. This study revealed that modulating Mcl-1 expression within HCC cells led to notable anti-tumor effects.

Identifying novel biomarkers or target molecules for poorly differentiated HCC is an urgent clinical need.[18] Poorly differentiated HCC is associated with aggressive tumor behavior, increased metastatic potential, and resistance to conventional therapies.[19] Therefore, developing a deeper understanding of the underlying molecular mechanisms and identifying specific biomarkers involved in the progression of poorly differentiated HCC could lead to improved prognosis and tailored therapeutic approaches.[20] However, to date, there is a lack of comprehensive studies investigating the role of SASP and its potential as a biomarker or therapeutic target in poorly differentiated HCC. In this study, the bile acid-mediated induction of HSC activation enhanced the invasion of HCC cells via the expression of SASP proteins, including IL-6.

The role of IL-6 in hepatocarcinogenesis has garnered significant attention owing to its multifaceted impact on tumorigenesis and tumor progression. As a pleiotropic cytokine, IL-6 is recognized for its involvement in chronic inflammation, immune regulation, and cell proliferation.[21] It has been shown that the serum IL-6 level is elevated in patients with HCC, and its increased expression is associated with poor prognosis and advanced disease stages. IL-6 has also been implicated in promoting the activation of HSCs, which are key players in the progression of liver fibrosis to HCC. Furthermore, IL-6 has been linked to the acquisition of SASP in cancer cells, contributing to a protumorigenic microenvironment by promoting inflammation, angiogenesis, and immunosuppression. A translational study on the bile acid-mediated induction of HSC activation and SASP in HCC sheds new light on the intricate mechanisms of hepatocarcinogenesis, suggesting a potential link between bile acid signaling, HSC activation [22], IL-6 expression, and the development of HCC. These findings underscore the critical role of IL-6 in orchestrating the molecular pathways that contribute to HCC progression and suggest that it is a potential target for therapeutic interventions to disrupt the hepatocarcinogenic process.

Mcl-1 has emerged as a pivotal factor in hepatocarcinogenesis, drawing attention from previous studies because of its significant impact on tumorigenesis and disease progression. Mcl-1[23], an anti-apoptotic member of the Bcl-2 protein family, has been implicated in regulating cell survival, resistance to apoptosis, and maintaining mitochondrial integrity. Furthermore, previous studies have suggested that Mcl-1 contributes to the evasion of apoptosis in HCC cells, enabling their survival and uncontrolled proliferation.[24] A translational study investigating the bile acid-mediated induction of HSC activation and SASP in HCC provided novel insights into the intricate mechanisms of hepatocarcinogenesis, offering potential connections between bile acid signaling, Mcl-1 expression, and the development of HCC. These findings underscore the crucial role of Mcl-1 in orchestrating the cellular pathways that fuel HCC progression and highlight its potential as a therapeutic target for interventions aimed at disrupting hepatocarcinogenesis.

There is an intriguing disparity between the significant effect of COX-2 observed in in vitro studies and its lack of a substantial impact on in vivo mouse models. Previous studies have indicated that in vitro systems often lack the complex microenvironment and interactions present in vivo, which can lead to differences in cellular behavior and its associated signaling pathways.[25] COX-2, an enzyme involved in prostaglandin synthesis and inflammation, has been linked to tumor promotion and progression by modulating the tumor microenvironment.[26] While an in vitro model might have provided an isolated view of the direct impact of COX-2 on HSC activation and Mcl-1 expression, the in vivo environment incorporates additional factors such as immune responses, systemic inflammation, and crosstalk between different cell types. To fully elucidate this discrepancy, future investigations should determine the intricate interplay between COX-2, HSC activation, and Mcl-1 expression within the dynamic in vivo milieu, providing a more comprehensive understanding of the role of COX-2 in HCC progression.[27]

One limitation of this study is that the role of Mcl-1 in hepatocarcinogenesis has not yet been elucidated in patients with poorly differentiated HCC. Future studies may prove that the inhibition of Mcl-1 could be a therapeutic target for patients with HCC. Nonetheless, the results of this study provide critical knowledge regarding the mechanistic link between bile acid signaling, HSC activation, and the SASP in HCC. Addressing these findings is essential for identifying novel therapeutic targets, such as Mcl-1, and developing innovative strategies to combat HCC progression.

In conclusion, Mcl-1 expression was modulated through a TGR-5-dependent mechanism in response to elevated IL-6 levels induced by SASP in the tumor microenvironment of HCC. This effect originates from the communication between HCC cells and HSCs. These findings may contribute to our understanding of the role of the SASP in hepatocarcinogenesis and provide novel insights into identifying the role of Mcl-1 in poorly differentiated HCC and sorafenib-resistant HCC cells. Ultimately, these findings have the potential to pave the way for the development of innovative therapeutic strategies to improve patient outcomes following HCC treatment.

Ethical statement

Ethics approval was obtained from the Ethics Committee of the National Cancer Center, Korea. This study was conducted in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health. The in vivo study protocol was approved by the Institutional Animal Care and Use Committee (NCC-22-771) of the National Cancer Center of Korea. All experiments involving human tissues were approved by the Institutional Review Board of the National Cancer Center (NCC2022-0200). Participant consent was waived by the Institutional Review Board of National Cancer Center, Korea

Author contributions

Conceived and designed the analysis: YC, ML, BHK, JWP

Collected the data: YC, ML, MJP, NJ

Contributed data or analysis tools: YC, ML, MJP, NJ, BHK, JWP

Performed the analysis: YC, ML MJP, NJ

Wrote the paper: YC, ML

All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

Authors disclose no conflicts of interest.

Acknowledgement

This work was supported by the Genomics Core Facility in National Cancer Center Korea. This work has supported by the National Research Foundation of Korea grant funded by the Korea government (2021R1A2C4001401), National Cancer Center, Korea (2210420), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (HI22C1948, HI22C0828).

Cho Y, Kim BH, Park JW. Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison Clinical and molecular hepatology. 2023;29:252–262; Cho Y, Kim BH, Park JW. The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea Clinical and molecular hepatology. 2023;29:99–101.
Zou G, Park JI. Wnt signaling in liver regeneration, disease, and cancer Clinical and molecular hepatology. 2023;29:33–50.
Finn RS, Qin S, Ikeda Met al.. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma The New England journal of medicine. 2020;382:1894–1905.
Cheng AL, Qin S, Ikeda Met al.. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Journal of hepatology. 2022;76:862–873.
Korean Liver Cancer A, National Cancer Center K. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma Clinical and molecular hepatology. 2022;28:583–705; Goh MJ, Sinn DH, Kim JMet al.. Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective Clinical and molecular hepatology. 2023;29:197–205.
Limousin W, Laurent-Puig P, Ziol Met al.. Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab Journal of hepatology. 2023;79:1450–1458.
Rosenberg N, Van Haele M, Lanton Tet al.. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling Journal of hepatology. 2022;77:1631–1641; Liu P, Tang Q, Chen Met al.. Hepatocellular Senescence: Immunosurveillance and Future Senescence-Induced Therapy in Hepatocellular Carcinoma Frontiers in oncology. 2020;10:589908.
Kim KM, Yoon J-H, Gwak G-Yet al.. Bile acid-mediated induction of cyclooxygenase-2 and Mcl-1 in hepatic stellate cells Biochemical and biophysical research communications. 2006;342:1108–1113; Yoon J-H, Werneburg NW, Higuchi Het al.. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism Cancer research. 2002;62:6500–6505.
Schmucker DL, Ohta M, Kanai S, Sato Y, Kitani K. Hepatic injury induced by bile salts: correlation between biochemical and morphological events Hepatology. 1990;12:1216–1221.
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells cell. 1998;93:705–716.
Cheng J, Fan X-M. Role of cyclooxygenase-2 in gastric cancer development and progression World journal of gastroenterology: WJG. 2013;19:7361.
Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions Blood. 1997;89:630–643.
Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium Cancer Res. 1982;42:3858–3863.
Lee JH, Ku JL, Park YJ, Lee KU, Kim WH, Park JG. Establishment and characterization of four human hepatocellular carcinoma cell lines containing hepatitis B virus DNA World J Gastroenterol. 1999;5:289–295.
Cho Y, Cho EJ, Lee JHet al.. Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2016;83:607–616.
Xu L, Hui AY, Albanis Eet al.. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis Gut. 2005;54:142–151.
Lee JH, Cho Y, Kim HYet al.. Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria Annals of surgery. 2016;263:842–850.
Sankar K, Gong J, Osipov Aet al.. Recent advances in the management of hepatocellular carcinoma Clinical and molecular hepatology. 2023.
Kurebayashi Y, Ojima H, Tsujikawa Het al.. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification Hepatology. 2018;68:1025–1041.
Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma Journal of hepatology. 2020;72:215–229.
Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine Advances in immunology. 1993;54:1–78.
Cho Y, Cho EJ, Lee JHet al.. Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma Digestive diseases and sciences. 2016;61:2568–2577.
Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1 Nature. 2003;426:671–676.
Weber A, Boger R, Vick Bet al.. Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice Hepatology. 2010;51:1226–1236.
Cekanova M, Rathore K. Animal models and therapeutic molecular targets of cancer: utility and limitations Drug design, development and therapy. 2014;8:1911–1921.
de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development Contributions to microbiology. 2006;13:118–137.
Bae SH, Jung ES, Park YMet al.. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398 Clinical cancer research: an official journal of the American Association for Cancer Research. 2001;7:1410–1418.

No competing interests reported.

SupplementaryDataChoetal.docx

Download PDF

Version 1

posted

You are reading this latest preprint version

Bile acid-mediated activation of hepatic stellate cells and myeloid cell leukemia- 1 triggers hepatocarcinogenesis

Status:

Version 1

Abstract

Objective

Methods

Results

Conclusion

Figures

Key Message

Introduction

Materials and Methods

Cell lines and co-culture

Cell proliferation analysis (MTT assay)

Small interfering RNA (siRNA) transfection

In vivo subcutaneous xenograft model

Human blood sample collection and cytokine measurement

Immunoblot analysis

Real-time polymerase chain reaction (qPCR) analysis

Statistical analyses

Ethics statement

Results

Bile acid significantly increased the invasion of HSCs

The selective inhibition of Mcl-1 or COX-2 attenuates HSC invasion and IL-8 production

Crosstalk of HCCs and HSCs increased SASP, COX2, and Mcl-1 levels

Upregulated mRNA expression of IL-6 in patients with HCC was correlated with poor overall survival

Discussion

Declarations

References

Additional Declarations

Supplementary Files

Status:

Version 1